94
Views
3
CrossRef citations to date
0
Altmetric
Article

A review of discrete event simulation in National Coordinating Centre for Health Technology Assessment-funded work and a case study exploring the cost-effectiveness of testing for thrombophilia in patients presenting with an initial idiopathic venous thromboembolism

, , &
Pages 14-23 | Received 15 Oct 2008, Accepted 03 Jun 2009, Published online: 19 Dec 2017
 

Abstract

A review of modelling work funded by the National Coordinating Centre for Health Technology Assessment (NCCHTA) was undertaken to quantify the use of discrete event simulation (DES) techniques in health economics. A case study, funded by the NCCHTA, estimating the cost-effectiveness of thrombophilia testing is presented. Thrombophilia may increase the risk of venous thromboembolism (VTE) which can be fatal; however, the preventative treatment, warfarin, is associated with an increased risk of haemorrhage, which is also potentially fatal. A DES model, populated from literature reviews and incorporating VTE events, haemorrhages and death was constructed. The most cost-effective duration of warfarin treatment (‘standard treatment’ of 3 or 6 months, 10 years, 20 years or lifelong) was estimated for patients with initial idiopathic VTE, sub-divided into age, gender, VTE type and known thrombophilia type groups. The primary goal was to ascertain, for each sub-group, whether the cost of thrombophilia testing for all patients, given subsequent tailoring of warfarin duration, would be cost-effective. Thrombophilia testing was estimated to be cost-effective in most sub-groups; however these results are subject to large uncertainty. Primary research is required before a definitive conclusion can be reached.

Acknowledgements

The following formed our clinical advisory group for the case study. Professor M Greaves, Dr T Baglin, Dr I Jennings, Dr S Kitchen and Dr M Makris. Funding for this project was provided by the National Collaborating Centre for Health Technology Assessment. The views expressed in this article do not represent those of the funder.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.